INTRODUCTION
Rare tumor types offer a unique opportunity to investigate and discover mechanisms of tumorigenesis. Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC), representing $5% of this heterogeneous group of cancers arising from the nephron (Stö rkel et al., 1997) , with 3,000 new cases annually in the United States (Jemal et al., 2013) . Although ChRCC typically exhibits an indolent pattern of local growth, with greater than 90% 10-year cancer-specific survival (Amin et al., 2002; Przybycin et al., 2011) , aggressive features and metastasis can occur. ChRCC is associated with a distinct aneuploidy pattern (Speicher et al., 1994) ; however, genomewide evaluation of its somatic mutation spectrum has not been reported. ChRCC is associated with germline mutation of FLCN in the autosomal-dominant cancer predisposition Birt-Hogg-Dubé (BHD) syndrome, in which 34% of BHDassociated kidney tumors are ChRCC (Nickerson et al., 2002; Pavlovich et al., 2002; Schmidt et al., 2001) , and with germline mutation of PTEN in Cowden syndrome (Shuch et al., 2013) . Previous studies have suggested a nonglycolytic metabolic profile for ChRCC, using 18 F-fluorodeoxyglucose positron emission tomography/computed tomography (Ho et al., 2012) , and have shown that the genomic profile comprises unique whole-chromosome losses rather than focal events (Speicher et al., 1994) .
Genomic profiling of rare cancers, such as ChRCC, can provide a more complete picture of the disease. Although very large sample numbers (>5,000) may be needed for some disease types in order to detect rare mutational events (Lawrence et al., 2014) , in many cases, there remain undiscovered frequent mutations that drive disease. When data integration across multiple platforms is applied, patterns observed in one data type may be reflected in the other data types, building a more conclusive set of findings with regard to revealing driver events. For example, early DNA microarray studies of breast cancer, for example, globally assaying a single data type for 65 tumors (Perou et al., 2000) and incorporating clinical data, have had an enduring impact on our understanding of breast and other cancers, while PBRM1 mutations were discovered in clear cell kidney cancers from an initial analysis of just 25 tumors (Varela et al., 2011) . Understudied cancers, such as ChRCC, may hold this potential for discovery as well.
RESULTS

Copy-Number and Whole-Exome Analysis
The Cancer Genome Atlas (TCGA) collected a total of 66 primary ChRCC specimens (Table S1 available online) with matching normal tissue/blood, in order to better characterize the molecular basis of this cancer using multiple data platforms (Table 1; Table S1 ). Our comprehensive analysis of ChRCC involved a systematic examination by data type, including copy number and whole-exome sequencing (WES). By SNP array analysis, loss of one copy of the entire chromosome, for most or all of chromosomes 1, 2, 6, 10, 13, and 17, was seen in the majority of cases (86%; Figure 1A ). Losses of chromosomes 3, 5, 8, 9, 11, 18, and 21 were also noted at significant frequencies (12%-58%). There were no focal copy-number events by GISTIC analysis (Mermel et al., 2011) , suggestive of a simpler chromosomal landscape for ChRCC in comparison with that of other cancers, including the more common clear cell type RCC (ccRCC). We subdivided our ChRCC cases according to previously defined histologic categories of ''classic'' (n = 47) , which demonstrate the classical pale cytoplasmic features for which the disease was named, and ''eosinophilic'' (n = 19), based on abundant, eosinophilic cytoplasm and densely packed mitochondria, by expert consensus pathology review (Brunelli et al., 2005) . Although all classic cases showed the characteristic ChRCC copy-number pattern, only about half of the eosinophilic cases (10 of 19) showed the same, with four eosinophilic cases showing no copy-number alterations. This suggests a degree of genomic heterogeneity that distinguishes the histopathology-based classifications.
WES of 66 ChRCC cases targeted $186,260 exons in $18,091 genes, achieving 90% target coverage at a minimum of 203 for both tumor and matched normal samples. Overall, ChRCC displayed a low median rate of exonic somatic mutations ($0.4 per Mb) compared with most tumors (Alexandrov et al., 2013) , approximately 3-fold less than the median number seen in ccRCC (which differences were also observable within
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Comprehensive Genomic Analysis of ChRCC strata defined by age or stage), with the one exception showing elevated somatic mutation rate (>10/Mb by WES) and mutation signature of DNA mismatch repair deficiency (Alexandrov et al., 2013) . Using alternative sequencing instrumentation, we validated 60 somatic mutation events for a set of 30 genes both arising from WES and having inferred biologically relevance (Table S2) . Although our lower case numbers limited purely data-driven approaches to assigning statistical significance to infrequently mutated genes, we did have sufficient power to identify significant genes with a frequency of $10% (Lawrence et al., 2014) . Only two significant genes were thus identified (MutSig q < 0.1): TP53 and PTEN.
TP53 was frequently mutated in 32% of cases (21 of the 66 profiled), with mutations correlating with decreased expression of p53 transcriptional targets (Figures S1A-S1C). PTEN was the next most frequently mutated, with 9% (6 of 66) nonsilent mutations detected. No other genes were found to be mutated at a frequency higher than 5%, though mutations involving cancer-relevant genes were found at lower frequencies (Figure 1B) . Mutations were seen in MTOR (2 cases), NRAS (1 activating mutation), and TSC1 or TSC2 (4 cases), and two homozygous deletions were seen in PTEN, indicating that genomic targeting of the mTOR pathway occurred overall in 15 (23%) of 66 ChRCCs ( Figure 1B ). Biological significance could be ascribed to infrequently mutated genes, in terms of associated pathways, including the p53 and PTEN pathways (Table S2 ). The genetic diseases BHD and tuberous sclerosis complex both predispose to the development of ChRCC, and associated mutations converge in activation of the PTEN signaling pathway. Our study focused on sporadic disease, and a surprisingly high percentage ($47%) of our core cases did not show alterations associated with either PTEN or p53 pathways. Because no additional pathways involving sizable numbers of cases could be implicated from the exome data, our search was extended to mtDNA and structural variant (SV) analysis, as described below.
DNA Methylation and RNA Analysis TCGA data platforms allow for comparisons between tumor types (Cancer Genome Atlas Research Network et al., 2013) . For example, we observed widespread differences in DNA methylation between ChRCC and ccRCC (Figure 2A ), involving over 64,000 loci out of $450,000 profiled (p < 0.001, t test using logit-transformed data, beta value difference > 0.1). ChRCC displayed more hypomethylation and fewer hypermethylation events compared with ccRCC. We also observed epigenetic silencing of CDKN2A/p16 in four ChRCC cases ( Figure 2B ). In principle, differential DNA methylation patterns could involve TERT promoter structural variant: See also Figure S1 and Table S2. cancer-relevant pathways but may also reflect the cell of origin of the cancer (Shen and Laird, 2013) . On the basis of immunohistochemical analyses (Prasad et al., 2007) , ChRCC has been postulated to arise from intercalated cells in the distal convoluted tubule of the nephron, while ccRCC is thought to arise from cells in the proximal convoluted tubule; however, this issue has remained unresolved. The above DNA methylation patterns were consistent with distinct origins, leading us to further explore these origins using gene expression data. We examined our gene expression data in the context of an external gene expression data set of normal tissue microdissected from various regions of the nephron (Cheval et al., 2012) . Supervised analysis, globally comparing each TCGA ChRCC or ccRCC tumor expression profile (n = 66 and n = 417, respectively) with that of each sample in the nephron atlas, showed high mRNA expression correlations for ChRCC with distal regions of the nephron. ccRCC gene expression, however, was correlated with patterns associated with the proximal nephron ( Figure 2C) . These associations were also evident when focusing on the subset of differential genes in ChRCC versus ccRCC associated with inverse DNA methylation changes ( Figure 2D ). These results put into context many of the widespread molecular differences between these two kidney cancer types, as well as suggesting that cancers may be defined in part by cell of origin in addition to genetic aberrations.
In addition to widespread differences in gene expression between ChRCC and ccRCC, and differences from normal kidney ( Figure S2A and Table S3 ), unsupervised clustering of mRNA profiles indicated further molecular heterogeneity within ChRCC, with at least two subsets identified ( Figure S2B ) as defined by differential gene expression patterns. Cluster analysis of micro-RNA (miRNA) profiles also indicated heterogeneity ( Figure S2C ), and we could identify anticorrelations between miRNAs and their predicted mRNA targets (Table S4) , including an anticorrelation (false discovery rate [FDR] < 0.01) involving miR-145 (low in ChRCC versus normal) and the complex I-associated NDUFA4 gene ( Figure S2D 
Comprehensive Genomic Analysis of ChRCC mRNA, miRNA, and DNA methylation (Table S5 ); many of these correlates were shared with those previously observed for ccRCC (Cancer Genome Atlas Research Network, 2013) and included cell cycle genes, but not the ''Warburg effect''-like patterns of aggressive ccRCC (Cancer Genome Atlas Research Network, 2013) .
Pathway and mtDNA Analysis
When viewed in the context of mitochondrial function, expression of nuclear-encoded genes in ChRCC, with compared to normal kidney, suggested increased utilization of the Krebs cycle and electron transport chain (ETC) for ATP generation ( Figure 3A ; Figures S3A and S3B ). In ChRCC, nearly all genes encoding enzymes in the Krebs cycle showed increased expression over normal, with the entry of pyruvate into the Krebs cycle via acetyl coenzyme A likely through the pyruvate dehydrogenase complex. Concordantly, all complexes of the ETC demonstrated mRNA increases in at least one gene. These patterns could reflect an increased level of mitochondrial biosynthesis, resulting in greater numbers of mitochondria within each tumor cell; this possibility is supported by both the increased expression of mitochondrial biogenesis regulator PPARGC1A (p < 1 3 10 À5 , t test using log-transformed data; Table S3 ) and increased mitochondrial genome copy numbers (four times more on average in ChRCC versus normal kidney; Figure 3B ; Figure S3C ). These findings interestingly parallel the eosinophilic histology observed in some ChRCC, corresponding to the high uptake of eosin by mitochondria. Eosinophilic ChRCC tumors share many features with the benign variant oncocytoma, which is also characterized by dense accumulations of mitochondria (Amin et al., 2008; Tickoo et al., 2000) . Furthermore, the gene expression landscape appeared very different from that of ccRCC, in which expression of genes involved in mitochondrial functions is strongly suppressed ( Figure S3D ) (Cancer Genome Atlas Research Network, 2013). These findings suggest that various bioenergetics strategies may support tumor growth and that A B Figure S3 .
not all cancers necessarily seek to minimize their reliance upon oxidative phosphorylation (Cancer Genome Atlas Research Network, 2013) . Given the indicated prevalent role of mitochondria in ChRCC and the likelihood of rapid mitochondrial genome replication ( Figure 3B ), we sequenced mtDNA from 61 of our 66 ChRCC cases, using a PCR-based amplification approach (Table S6 ). In all, we identified 142 somatic mutation events (i.e., not present in the normal) at various levels of heteroplasmy (i.e., mixture with other variants), 75 of these residing within the commonly altered D-loop noncoding region (Chatterjee et al., 2006) . Thirty-five mutation events (involving 27 cases) were present in over 50% of mtDNA copies in the tumor (>50% heteroplasmy) ( Figure 4A ). Human mtDNA encodes 13 proteins involved in respiration and oxidative phosphorylation ( Figure 3A ), and we found 15 nonsilent mutations in 12 ChRCC cases involving these genes (>50% heteroplasmy), all of which validated using alternative strategies, including whole-genome sequencing (WGS)-based analysis (Larman et al., 2012) (Table S6 ). On the basis of previous functional studies in oncocytoma (Gasparre et al., 2008; Mayr et al., 2008; Simonnet et al., 2003) , and because many of our variants represented frameshift substitutions, these mtDNA mutations are thought, in general, to lead to inactivation, rather than activation, of the associated protein.
ETC complex I genes were altered in 18% of cases (n = 11; Figures 1B and 3A; Table S3 ); the most frequently altered gene was MT-ND5, in six cases (all with >70% heteroplasmy), with five of these being histologically classified as eosinophilic ChRCC (p < 0.01, one-sided Fisher's exact test) and three showing no copy-number abnormalities (p < 0.002). MT-ND5 is essential for the activity of complex I (Chomyn, 2001) , which is responsible for the transfer of electrons from NADH to ubiquinone. One ChRCC case had a single base insertion at position 12417 that changes the length of an 8-bp homopolymer tract in MT-ND5, which has been observed previously in several other cancer types (Larman et al., 2012) ; another case had an insertion at 12384, at which position a mutation was found elsewhere in oncocytoma and associated with loss of complex I activity (Mayr et al., 2008) . Two ChRCC cases each had single-base deletions at position 13230 of MT-ND5, but no other mtDNA
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Comprehensive Genomic Analysis of ChRCC Cancer Cell 26, 1-12, September 8, 2014 ª2014 Elsevier Inc. 5 mutations were recurrent in our cases. We also found MT-ND5mutated ChRCC cases to have a distinct gene transcription signature ( Figure 4B ; Figures S4A and S4B; 719 genes with p < 0.001 by t test, FDR < 0.05), which was shared by other eosinophilic cases and not limited to genes in regions of recurrent copy-number abnormality ( Figure S4C ). Genes with high expression in MT-ND5-mutated cases were enriched for those associated with mitochondria (43 with Gene Ontology term ''mitochondrion;'' p < 5 3 10 À6 , one-sided Fisher's exact test), including several with roles in ETC (SDHB, NDUFS1, ATP5F1, COX10, and COX11; Table S3 ). Notably, mutations in complex I did not result in expression patterns associated with loss of oxidative phosphorylation ( Figure 4C ), as might be assumed (Larman et al., 2012) , suggesting possible alternative roles for complex I alteration in cancer-associated metabolic activity ( Figure S4D ). The associations made here, involving mtDNA mutations with mitochondrial abundance and differential gene expression patterns (which may be unique to ChRCC and related cancers), could perhaps suggest either a compensatory role for loss of complex I function or selective pressures operating to promote alternative pathways.
Whole-Genome Analysis WGS for 50 of our 66 ChRCC cases was performed (603 and 303 coverage for paired tumor and normal, respectively). The Meerkat algorithm (Yang et al., 2013) was applied to detect genomic rearrangements, with an average of 16 found per case (range 0-207; Figure S5A ), but without involving recurrent gene-gene fusions. By WGS analysis, a subset of ChRCC manifested kataegis ( Figure 5A ; Figure S5B ), a phenomenon involving highly localized substitution mutations (C > T or C > G). Consistent with observations in other cancers (Alexandrov et al., 2013; Nik-Zainal et al., 2012) , we found that regions of kataegis in ChRCC were in the vicinity of genomic rearrangements ( Figure 5A ; Figure S5B ; average of 150 rearrangements by pter/qter region). Three ChRCC WGS profiles showed particularly strong patterns involving chromosomal region 3p, 5p, 5q, 8q, 13q, or 15q ( Figure 5B) . A mutation signature consistent with APOBEC cytidine deaminase activity (Alexandrov et al., 2013; Roberts et al., 2013) was significantly enriched in kataegis regions as well as in tightly spaced mutation clusters forming kataegis events ( Figures S5C-S5F and Table S7 ). Although not detectable in ChRCC WES data (Alexandrov et al., 2013) , WGS mutation spectra of six ChRCC cases, including the three with strong kataegis patterns, showed statistically significant (albeit moderate) APOBEC-patterned mutagenesis across the entire genome ( Figure S5C ). APOBEC3B mRNA expression was also elevated in ChRCC compared with normal kidney ( Figure S5G) .
We compared gene expression profiles between ChRCC cases with and without a strong kataegis pattern (n = 3 and n = 47, respectively) and identified 29 differentially expressed genes (FDR < 0.05) including TERT (p < 1 3 10 À10 , t test, FDR < 1 3 10 À6 ; Figure 5C ). The TERT gene itself showed a wide range of expression levels across ChRCC, from undetectable to hundreds of units by RNA sequencing. Focusing our Figure S4 and Table S6 .
Comprehensive Genomic Analysis of ChRCC attention on TERT, we sequenced the promoter region for recently identified mutations (C228T and C250T) (Huang et al., 2013) ; three cases harbored C228T mutations but were associated with only marginal TERT expression levels (average expres-sion $1 unit). WGS analysis of DNA copy within the TERT region identified some copy-number variation, but not at levels that would account for the extent of deregulated expression. However, multiple cases did show abrupt changes in copy number, (E) TERT expression levels in the ChRCC cases with TERT promoter SV, in the ChRCC cases with TERT promoter mutation (SNV), and in the remaining cases, as well as in normal kidney samples; p values by two-sided t test on log-transformed data. Box plots represent 5%, 25%, median, 75%, and 95%. See also Figure S5 and Table S7 .
Comprehensive Genomic Analysis of ChRCC at points that fell within the region 10 kb upstream of the TERT transcription start site ( Figure 5D ). This observation suggested the existence of structural breakpoints, leading us to reexamine our Meerkat-generated results with greater scrutiny. Subsequent WGS analysis identified genomic rearrangements involving the TERT promoter region, leading to breakpoints within the region in six out of 50 ChRCC cases ( Figure 5D and Table 2 ); these cases also had the highest levels of TERT expression (average > 500 units, p < 1 3 10 À20 , t test; Table 2 and Figure 5E ), even compared with cases with 228T mutation, and three showed the strongest manifestation of kataegis (p = 0.001, one-sided Fisher's exact). In five ChRCC cases, the TERT-associated rearrangements were intrachromosomal (one involving part of PDCD6), while the sixth case involved NEK5 on chromosome 13. When considering intratumor heterogeneity, in most cases, these variants were estimated to reside in nearly all of the cells (when counting the numbers of concordant versus discordant read pairs), which would indicate that the TERT-associated rearrangements represent early events and therefore possible drivers. Of the seven rearrangements identified by WGS, we confirmed six (involving six cases) by PCR, by designing primers that spanned both sides of the breakpoint junction ( Figure 6A ; Table S8 ), allowing amplification of DNA spanning the breakpoint region in the tumor sample ( Figure 6B ; Figure S6 ); subsequent sequencing of the PCR product independently confirmed the junction in each case ( Figure 6C ). Although point mutations in the TERT promoter, leading to upregulation of TERT itself, have been recently reported in cancers such as melanoma (Heidenreich et al., 2014; Huang et al., 2013) , our results represent another phenomenon, of recurrent genomic rearrangement breakpoints in the TERT promoter being associated with elevated TERT expression in cancer. A precise mechanism remains to be elucidated, though, as a result of rearrangement, a number of cis-regulatory elements were found to be placed in close proximity to the core promoter of TERT ( Figure S7 ).
DISCUSSION
With this comprehensive molecular survey of ChRCC, we have made several important findings, in particular the observed recurrent genomic structural rearrangements involving the TERT promoter region and elevated TERT expression, and our results raise intriguing questions regarding cancer, involving the role of mtDNA alterations and the role of the cell of origin. The above key findings were made possible only by our comprehensive approach, whereby, for example, we had no prior hypotheses regarding TERT at the outset of our study. Additionally, mtDNA mutations in cancer, particularly those involving MT-ND5 and complex I, have been hypothesized elsewhere to recapitulate the Warburg effect (Larman et al., 2012) , though the corresponding expression and histological patterns observed in our data were consistent with a complex metabolic phenotype rather than simple loss of oxidative phosphorylation. Taken together, our key findings further illustrate the need to survey cancers outside of exome boundaries, for example, by incorporating WGS or mtDNA sequencing as part of an integrative, multiplatform analysis.
Through integration of molecular data from less common cancers, we can learn more about more frequently encountered diseases. Here, for example, our analysis of ChRCC led to additional insights regarding ccRCC. RCC represents a collection of highly distinct tumors arising from different lineages within the nephron, with distinct molecular and genetic features reflecting independent processes of tumorigenesis (Linehan, 2012) . Given the complexity of function assigned to an organ such as the kidney, different cancers arising from this organ may not necessarily appear similar to each other (Alexandrov et al., 2013; Cancer Genome Atlas Network, 2012) . Our multiplatform analyses clearly confirm that ChRCC is a distinct disease entity from, and shares little cell lineage or genomic characteristics with, ccRCC, further reinforcing the notion that disease-specific therapies are needed for rarer tumors such as ChRCC, rather than simply adopting conventional therapeutic strategies used for ccRCC. Given the clear genetic differences between ChRCC and ccRCC, our results would suggest cell of origin as a key factor in disease determination, observations that could inform future efforts to fractionate the pool of susceptible cells for ChRCC or ccRCC modeling or preventative interventions. In addition, these data will serve as a resource for future explorations of other tumors of kidney origin, such as papillary RCCs, while being broadly relevant as well to the study of other cancers, Figure S7 . a Denotes whether the upstream (+1) or downstream (À1) sequence was fused relative to the given coordinates. b Across 66 ChRCC cases, 90th percentile of expression for TERT mRNA was 5.28 units by RNA sequencing. c Confirmation using PCR across breakpoint junction, with subsequent sequencing of PCR product by PacBio platform. No PCR product was successfully obtained for one of the two breakpoints for KL-8323, likely due in part to the complexity of rearrangements in this case.
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Comprehensive Genomic Analysis of ChRCC as metabolic, genomic structural alterations, and cellular factors that influence the spectrum of genetic events contributing to cancer development are further realized. The gene expression patterns, increased mitochondrial numbers, and histological patterns associated with ChRCC all See also Figure S6 and Table S8 .
indicate an increased importance of a distinct mitochondrial respiration program in this disease. Renal oncocytoma, a benign renal tumor that, like ChRCC, may also arise from the distal nephron, shares several similarities with ChRCC (particularly with its eosinophilic subtype), including abundant, eosinophilic cytoplasm and densely packed mitochondria (Amin et al., 2008; Tickoo et al., 2000) . Mitochondrial accumulation in renal oncocytomas has been hypothesized to be a compensatory mechanism for inefficient oxidative phosphorylation (Simonnet et al., 2003) , whereby loss of complex I activity may result from somatically acquired homoplasmic mutations in mitochondrial complex I genes (Gasparre et al., 2008; Mayr et al., 2008; Simonnet et al., 2003) . However, gene expression in ChRCC would indicate that increased oxidative phosphorylation is maintained in complex I-altered tumors, suggesting a metabolic shift supporting the growth of this tumor, and counter to the Warburg-like phenomenon observed in high-grade, high-stage ccRCC and many other cancers (Cancer Genome Atlas Research Network, 2013) , which would appear consistent with previous observations, using metabolic imaging to demonstrate uptake of radiolabeled acetate but not glucose in ChRCC (Ho et al., 2012) . In general, cancer cells derive much of their ATP through oxidative phosphorylation (Ward and Thompson, 2012) , and cancer-associated reprogramming of mitochondria and of other metabolic pathways, besides glycolysis and the Warburg effect, has recently received much attention (Currie et al., 2013; Ward and Thompson, 2012) . Further studies to dissect the precise role of mtDNA alterations in cancer, and mitochondrial activities promoting cancer growth, could shed light on how core metabolic pathways may be altered in ChRCC and other malignant diseases.
Our finding of recurrent DNA rearrangement breakpoints within the TERT promoter region in over 10% of evaluated cases represents a mechanism for increased TERT expression in cancer different from point mutations observed in a wide variety of cancers (Heidenreich et al., 2014; Huang et al., 2013) , gene amplification (Weir et al., 2007; Chudnovsky et al., 2005) , and germline polymorphisms (Rafnar et al., 2009) . TERT is well recognized as having roles in telomere maintenance and DNA repair, in which deregulation of telomerase is a ubiquitous feature of human cancers. The previously observed TERT promoter mutations (C228T and C250T) create de novo E-twentysix/ternary complex factors binding sites, which have been observed to increase transcriptional activity from the promoter by 2-to 4-fold (Huang et al., 2013) . Interestingly, the TERT expression levels of the six cases with independently validated TERT promoter rearrangements were much higher than those cases with C228T promoter mutations, suggesting that these rearrangements might have an even more potent effect on upregulation of the gene. The precise mechanism of how these rearrangements affect expression remains to be elucidated; they could possibly involve rearranged cis-regulatory elements or could allow the core TERT promoter to escape from the native condensed chromatin environment (Zhao et al., 2009) . The observed association of TERT with kataegis is also intriguing. Elsewhere, rearrangement of DNA sequences upstream of TERT has been reported in immortalized, nontumorigenic fibroblasts, leading to activated telomerase in cells surviving the crisis stage of immortalization (Zhao et al., 2009) , which involves chromosomal instability and rearrangements due to loss of telomere capping activity; in the setting of human cancer, this would suggest that TERT-associated rearrangements would be involved in many cases at an early stage in tumorigenesis.
Future applications of the information presented here will include comparative analysis with other cancer types, for the possible existence elsewhere of structural rearrangements involving promoters for TERT or for other key drivers. As a resource with a large set of whole-genome sequences, integrated with a broad array of high-quality platform data sets, other relationships between genomic structural alterations and transcriptional components, including noncoding RNAs, remain to be uncovered. As our data represent single biopsies, future studies might focus on heterogeneity between biopsies from the same tumor (Gerlinger et al., 2012) ; additionally, subclonal analysis may shed light on early versus late somatic events in ChRCC tumorigenesis. Our study also revealed that divergent approaches for uncovering mtDNA mutations (long-range PCR [LR-PCR] versus WGS [Larman et al., 2012] ) are highly complementary to each other, allowing WGS data from other cancers to be similarly mined for mtDNA mutations, with the additional step of combining these data with those of other platforms, in order to better understand the role of the mitochondria in cancer. Finally, the underlying data sets presented here represent part of an interlocking toolset, which can be combined with those of other cancers (Cancer Genome Atlas Research Network et al., 2013) , for further discovery of driver alterations, both within and beyond the exome.
EXPERIMENTAL PROCEDURES
Patient and Sample Characteristics
With informed consent, biospecimens were collected from newly diagnosed patients with ChRCC undergoing surgical resection and who had received no prior treatment for their disease. Samples were obtained with approval from institutional review boards at Brigham and Women's Hospital, Memorial Sloan-Kettering Cancer Center, the National Cancer Institute, and The University of Texas MD Anderson Cancer Center. Using a coisolation protocol, DNA and RNA were purified. Details of sample preparation are described in Supplemental Experimental Procedures.
Data Generation
In total, 66 ChRCC cases were assayed on at least one molecular profiling platform (Table 1) , which platforms included (1) RNA sequencing, (2) DNA methylation arrays, (3) miRNA sequencing, (4) Affymetrix SNP arrays, (5) WES, (6) WGS, and (7) mtDNA sequencing (using LR-PCR to amplify mtDNA). As described above and in Supplemental Experimental Procedures, both single-platform analyses and integrated cross-platform analyses were performed. Sequence files are available from CGHub (https://cghub.ucsc.edu). All other molecular, clinical, and pathological data are available through the TCGA Data Portal (https://tcga-data.nci.nih.gov/tcga/).
WGS and WES Analysis
Massively parallel sequencing exome capture was performed using Nimble-Gen (custom designed) VCRome 2.1 (42 MB) according the manufacturer's instructions. All exome sequencing and WGS was performed on the Illumina HiSeq platforms. Basic alignment and initial sequence analysis were carried out using the Mercury analysis pipeline (Reid et al., 2014) .
mtDNA Sequencing Analysis mtDNA was isolated from tissue samples using LR-PCR methods. Amplified mtDNA PCR products were constructed into Illumina paired-end libraries, and raw sequence data were preprocessed and aligned using the Mercury pipeline.
RNA Sequencing Analysis
Both mRNA and miRNA libraries were separately generated from total RNA and constructed using manufacturer protocols. Sequencing was done on the Illumina HiSeq platform. Read mapping and downstream data analysis were performed as described in Supplemental Experimental Procedures.
Array Data Analysis
DNA was hybridized to Affymetrix SNP 6.0 arrays and Illumina Infinium HumanMethylation450 (HM450) BeadChip arrays, according to manufacturer protocols.
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